NewAmsterdam Pharma Company N.V. Adjustments For Increase Decrease In Other Operating Payables
NewAmsterdam Pharma Company N.V. (NAMS) reported Adjustments For Increase Decrease In Other Operating Payables of EUR 2.89 million for the 6-month period ending 2023-06-30, per its 6-K filed 2023-08-07.
Financial Statements › Notes
ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables · last filed 2024-10-28
| Period end | Adjustments For Increase Decrease In Other Operating Payables 6 month | Adjustments For Increase Decrease In Other Operating Payables 12 month |
|---|---|---|
| 2023-06-30 | 2.89M EUR 6-K · filed 2023-08-07 | |
| 2022-12-31 | -2.06M EUR 20-F/A · filed 2024-10-28 | |
| 2022-06-30 | 1.73M EUR 6-K · filed 2023-08-07 | |
| 2021-12-31 | 8.25M EUR 20-F/A · filed 2024-10-28 | |
| 2020-12-31 | 829.00K EUR 20-F/A · filed 2024-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |